An independent predictor of poor prognosis in locally advanced rectal cancer: rs867228 in formyl peptide receptor 1 (FPR1). (1st January 2021)

• Record Type: Journal Article
• Authors: Chiang, Shu-Fen; Huang, Kevin Chih-Yang; Chen, William Tzu-Liang; Chen, Tsung-Wei; Ke, Tao-Wei; Chao, K. S. Clifford
• Is Part Of: Oncoimmunology. Volume 10:Number 1(2021)
• Publication Date: 2021-01-01
• Subjects: FPR1 -- CCRT -- ICD -- DAMP -- antitumor immunity; Tumors -- Immunological aspects -- Periodicals; Neoplasms -- therapy -- Periodicals; Immunotherapy -- Periodicals; 616.994
• DOI: 10.1080/2162402X.2021.1926074
• Languages: English
• ISSNs: 2162-402X

Abstract

ABSTRACT: Formyl peptide receptor 1 (FPR1) plays a key regulatory role in innate and adaptive immunity. Recently, we reported that the CC genotype of FPR1-E346A (rs867228, c. 1037 A > C) is an independent biomarker for patients with locally advanced rectal cancer (LARC) who received preoperative concurrent chemoradiotherapy (CCRT). Pharmacologic inhibition of FPR1 decreased the migration and infiltration of T lymphocytes into tumor microenvironment after CCRT.